Jeffrey Chodakewitz Sells 5,122 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 5,122 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $150.82, for a total transaction of $772,500.04. Following the transaction, the chief marketing officer now directly owns 73,485 shares in the company, valued at approximately $11,083,007.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Monday, February 5th, Jeffrey Chodakewitz sold 3,594 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $161.46, for a total transaction of $580,287.24.
  • On Friday, February 2nd, Jeffrey Chodakewitz sold 3,696 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $166.79, for a total transaction of $616,455.84.
  • On Tuesday, January 16th, Jeffrey Chodakewitz sold 1,719 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $157.28, for a total transaction of $270,364.32.
  • On Tuesday, January 2nd, Jeffrey Chodakewitz sold 3,438 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $151.80, for a total transaction of $521,888.40.

Vertex Pharmaceuticals Incorporated (VRTX) traded up $3.12 on Wednesday, hitting $157.26. The stock had a trading volume of 1,901,860 shares, compared to its average volume of 2,090,000. The company has a market capitalization of $39,770.00, a PE ratio of 80.65, a PEG ratio of 2.21 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.58 and a current ratio of 4.79. Vertex Pharmaceuticals Incorporated has a 52 week low of $84.39 and a 52 week high of $174.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. The company had revenue of $651.63 million for the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The business’s revenue for the quarter was up 42.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 earnings per share. equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 1.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals announced that its board has authorized a share buyback plan on Wednesday, January 31st that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the pharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC raised its holdings in shares of Vertex Pharmaceuticals by 337.6% during the fourth quarter. Advisory Services Network LLC now owns 792 shares of the pharmaceutical company’s stock valued at $119,000 after buying an additional 611 shares during the last quarter. Smithfield Trust Co. acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $135,000. Whittier Trust Co. increased its stake in shares of Vertex Pharmaceuticals by 153.5% during the fourth quarter. Whittier Trust Co. now owns 991 shares of the pharmaceutical company’s stock valued at $149,000 after acquiring an additional 600 shares during the period. FNY Managed Accounts LLC acquired a new position in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $162,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $201,000. 92.84% of the stock is currently owned by institutional investors.

VRTX has been the topic of several research analyst reports. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, January 21st. Cowen reaffirmed a “buy” rating and set a $200.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, December 11th. Bank of America raised shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Friday, January 5th. Deutsche Bank initiated coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $175.00 price target on the stock. Finally, Royal Bank of Canada raised their target price on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $183.11.

TRADEMARK VIOLATION WARNING: “Jeffrey Chodakewitz Sells 5,122 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/jeffrey-chodakewitz-sells-5122-shares-of-vertex-pharmaceuticals-incorporated-vrtx-stock.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply